The University of Chicago Header Logo

Connection

Barry G. Arnason to Middle Aged

Back to Details
This is a "connection" page, showing publications Barry G. Arnason has written about Middle Aged.
Barry G. Arnason
Connection Strength
0.285
Middle Aged
  1. Immunoglobulin-like transcript 3, an inhibitor of T cell activation, is reduced on blood monocytes during multiple sclerosis relapses and is induced by interferon beta-1b. Mult Scler. 2010 Jan; 16(1):30-8.
    View in: PubMed
    Score: 0.024
  2. Terbutaline in myasthenia gravis: a pilot study. J Neurol Sci. 2009 Feb 15; 277(1-2):150-4.
    View in: PubMed
    Score: 0.022
  3. Etretinate augments interferon beta-1b effects on suppressor cells in multiple sclerosis. Arch Neurol. 2001 Jan; 58(1):87-90.
    View in: PubMed
    Score: 0.013
  4. Interferon-ß corrects massive gene dysregulation in multiple sclerosis: Short-term and long-term effects on immune regulation and neuroprotection. EBioMedicine. 2019 Nov; 49:269-283.
    View in: PubMed
    Score: 0.012
  5. Effect of HLA-DRB1 alleles and genetic variants on the development of neutralizing antibodies to interferon beta in the BEYOND and BENEFIT trials. Mult Scler. 2019 04; 25(4):565-573.
    View in: PubMed
    Score: 0.011
  6. Improved delayed visual reproduction test performance in multiple sclerosis patients receiving interferon beta-1b. Neurology. 1996 Dec; 47(6):1463-8.
    View in: PubMed
    Score: 0.010
  7. Incidence and course of depression in multiple sclerosis in the multinational BEYOND trial. J Neurol. 2016 Jul; 263(7):1418-26.
    View in: PubMed
    Score: 0.009
  8. Association of Vitamin D Levels With Multiple Sclerosis Activity and Progression in Patients Receiving Interferon Beta-1b. JAMA Neurol. 2015 Dec; 72(12):1458-65.
    View in: PubMed
    Score: 0.009
  9. Interferon-gamma-secreting cells in multiple sclerosis patients treated with interferon beta-1b. Neurology. 1995 Dec; 45(12):2173-7.
    View in: PubMed
    Score: 0.009
  10. Predictors of disease activity in 857 patients with MS treated with interferon beta-1b. J Neurol. 2015 Nov; 262(11):2466-71.
    View in: PubMed
    Score: 0.009
  11. Trigeminal neuralgia in multiple sclerosis relieved by a prostaglandin E analogue. Neurology. 1995 Jun; 45(6):1097-100.
    View in: PubMed
    Score: 0.009
  12. Interferon gamma- and interleukin-4-secreting cells in multiple sclerosis. J Neuroimmunol. 1993 Jul; 46(1-2):123-8.
    View in: PubMed
    Score: 0.008
  13. The hu-SCID myasthenic mouse. A new tool for the investigation of seronegative myasthenia gravis. Ann N Y Acad Sci. 1993 Jun 21; 681:303-5.
    View in: PubMed
    Score: 0.008
  14. Efficacy and safety of interferon beta-1b sc in older RRMS patients--a posthoc analysis of the BEYOND study. J Neurol. 2013 Jul; 260(7):1838-45.
    View in: PubMed
    Score: 0.007
  15. Increased muscarinic cholinergic receptor density on CD4+ lymphocytes in progressive multiple sclerosis. J Neuroimmunol. 1992 Feb; 36(2-3):171-7.
    View in: PubMed
    Score: 0.007
  16. Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci. Ann Neurol. 2011 Dec; 70(6):897-912.
    View in: PubMed
    Score: 0.007
  17. Neutralizing antibodies to interferon beta-1b multiple sclerosis: a clinico-radiographic paradox in the BEYOND trial. Mult Scler. 2012 Feb; 18(2):181-95.
    View in: PubMed
    Score: 0.007
  18. Increased lymphocyte beta-adrenergic receptor density in progressive multiple sclerosis is specific for the CD8+, CD28- suppressor cell. Ann Neurol. 1991 Jul; 30(1):42-7.
    View in: PubMed
    Score: 0.007
  19. Sympathetic skin responses are decreased and lymphocyte beta-adrenergic receptors are increased in progressive multiple sclerosis. Ann Neurol. 1990 Apr; 27(4):366-72.
    View in: PubMed
    Score: 0.006
  20. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol. 2009 Oct; 8(10):889-97.
    View in: PubMed
    Score: 0.006
  21. Minor salivary gland inflammation in Devic's disease and longitudinally extensive myelitis. Mult Scler. 2008 Jul; 14(6):809-14.
    View in: PubMed
    Score: 0.005
  22. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study. Clin Ther. 2008 Jun; 30(6):1102-12.
    View in: PubMed
    Score: 0.005
  23. HLA antigens in narcolepsy. Neurology. 1987 Dec; 37(12):1858-60.
    View in: PubMed
    Score: 0.005
  24. Suppressor and cytolytic cell function in multiple sclerosis. Effects of cyclosporine A and interleukin 2. J Clin Invest. 1986 Aug; 78(2):582-6.
    View in: PubMed
    Score: 0.005
  25. Effect of myasthenia serum and anti-acetylcholine receptor monoclonal antibody on the distributions of T-cell subsets in myasthenia patients and normal subjects. Asian Pac J Allergy Immunol. 1985 Jun; 3(1):30-6.
    View in: PubMed
    Score: 0.004
  26. Multiple sclerosis: relation of in vitro IgG secretion to T suppressor cell number and function. Neurology. 1984 Sep; 34(9):1155-60.
    View in: PubMed
    Score: 0.004
  27. Neuropathy accompanying IgM lambda monoclonal gammopathy. Acta Neuropathol. 1983; 59(4):255-61.
    View in: PubMed
    Score: 0.004
  28. A biochemically distinct sub-population of neurons in the human substantia gelatinosa. Study with G-6-PD histochemistry. J Neurol Sci. 1982 Aug; 55(2):175-83.
    View in: PubMed
    Score: 0.004
  29. Muscle acid protease activity in amyotrophic lateral sclerosis: correlation with clinical and pathologic features. Neurology. 1982 Aug; 32(8):901-3.
    View in: PubMed
    Score: 0.004
  30. Defective mitogenic responses in myasthenia gravis and multiple sclerosis. Ann Neurol. 1982 May; 11(5):456-62.
    View in: PubMed
    Score: 0.004
  31. Multiple sclerosis: current concepts and management. Hosp Pract (Off Ed). 1982 Feb; 17(2):81-9.
    View in: PubMed
    Score: 0.003
  32. Influence of azathioprine (imuran) on in vitro immune function in multiple sclerosis. Ann Neurol. 1982 Feb; 11(2):177-81.
    View in: PubMed
    Score: 0.003
  33. Comparison of agar gel electrophoresis and isoelectric focusing in multiple sclerosis and subacute sclerosing panencephalitis. Ann Neurol. 1981 Jan; 9(1):34-41.
    View in: PubMed
    Score: 0.003
  34. Changes in concanavalin A capping of human lymphocytes with age. Mech Ageing Dev. 1980 Apr; 12(4):331-7.
    View in: PubMed
    Score: 0.003
  35. Huntington's disease: abnormality of lymphocyte capping. Ann Neurol. 1979 Nov; 6(5):447-50.
    View in: PubMed
    Score: 0.003
  36. Suppressor cell function in man: evidence for altered sensitivity of responder cells with age. Clin Immunol Immunopathol. 1979 Jun; 13(2):119-24.
    View in: PubMed
    Score: 0.003
  37. Cellular immunity to acetylcholine receptor in myasthenia gravis: relationship to histocompatibility type and antigenic site. Neurology. 1979 Mar; 29(3):291-6.
    View in: PubMed
    Score: 0.003
  38. Mitogen responsiveness and suppressor cell function in multiple sclerosis. Influence of age and disease activity. Neurology. 1978 Oct; 28(10):999-1003.
    View in: PubMed
    Score: 0.003
  39. Suppressor cell function in multiple sclerosis. Ann Immunol (Paris). 1978 Feb-Mar; 129(2-3):159-70.
    View in: PubMed
    Score: 0.003
  40. Contrasting defects of T-lymphocyte mitogenic response in multiple sclerosis and myasthenia gravis. Trans Am Neurol Assoc. 1978; 103:191-3.
    View in: PubMed
    Score: 0.003
  41. Validation of the functional assessment of multiple sclerosis quality of life instrument. Neurology. 1996 Jul; 47(1):129-39.
    View in: PubMed
    Score: 0.002
  42. Cellular immunity in myasthenia gravis. Response to purified acetylcholine receptor and autologous thymocytes. N Engl J Med. 1976 Mar 25; 294(13):694-8.
    View in: PubMed
    Score: 0.002
  43. Neutralizing antibodies to poliovirus and mumps virus in amyotrophic lateral sclerosis. J Neurol Sci. 1974 Dec; 23(4):537-40.
    View in: PubMed
    Score: 0.002
  44. Cell-mediated immunity in polymyositis. Creatine phosphokinase release from muscle cultures. Arch Neurol. 1974 Sep; 31(3):192-6.
    View in: PubMed
    Score: 0.002
  45. Histocompatibility types and measles antibodies in multiple sclerosis and optic neuritis. J Neurol Sci. 1974 Aug; 22(4):419-28.
    View in: PubMed
    Score: 0.002
  46. Comparison of T8+ cell-mediated suppressor and cytotoxic functions in multiple sclerosis. J Neuroimmunol. 1986 Sep; 12(3):215-24.
    View in: PubMed
    Score: 0.001
  47. Paraneoplastic myelopathy: antibodies against protein in normal spinal cord and underlying neoplasm. Lancet. 1985 Jul 06; 2(8445):49-50.
    View in: PubMed
    Score: 0.001
  48. The thymus gland in elderly patients with myasthenia gravis. Neurology. 1975 Mar; 25(3):294-5.
    View in: PubMed
    Score: 0.001
  49. Parainfluenza, histocompatibility, and multiple sclerosis. Association of parainfluenza antibodies and histocompatibility types in MS and optic neuritis. Arch Neurol. 1974 Apr; 30(4):327-9.
    View in: PubMed
    Score: 0.001
  50. The role of thymectomy in the treatment of myasthenia gravis. Ann N Y Acad Sci. 1971 Sep 15; 183:308-15.
    View in: PubMed
    Score: 0.000
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.